CSIMarket Company Name, Ticker, Customers, else..
 
Niagen Bioscience Inc   (NASDAQ: NAGE)
 
Price: $2.1240 $0.05 2.609%
Day's High: $2.128999948501587 Week Perf: -10 %
Day's Low: $ 2.07 30 Day Perf: -21.04 %
Volume (M): 75,702 52 Wk High: $ 7.28
Volume (M$): $ 0 52 Wk Avg: $4.37
Open: $2.10 52 Wk Low: $2.04



 Market Capitalization (Millions $) 168
 Shares Outstanding (Millions) 79
 Employees 117
 Revenues (TTM) (Millions $) 122
 Net Income (TTM) (Millions $) 10
 Cash Flow (TTM) (Millions $) 2
 Capital Exp. (TTM) (Millions $) 0

Business Description


Niagen Bioscience, Inc. is a global bioscience company focused on researching and commercializing nicotinamide adenine dinucleotide (NAD+) precursors, including their proprietary ingredient Niagen®, a form of vitamin B3. The company develops and supplies food-grade and pharmaceutical-grade Niagen® for use in dietary supplements, food products, and prescription compounding. Niagen Bioscience also markets consumer products under the Tru Niagen® brand through direct-to-consumer and international channels.


   Company Address: 10900 Wilshire Blvd Los Angeles 90024 CA
   Company Phone Number: 388-6706   Stock Exchange / Ticker: NASDAQ NAGE


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Business Update

Niagen Bioscience Innovates Resilience Navigating Tariffs in the Pursuit of Healthy Aging,

Published Mon, Apr 7 2025 4:26 PM UTC

In a rapidly changing global economic landscape, Niagen Bioscience, Inc. (NASDAQ: NAGE), formerly known as ChromaDex Corp. reaffirms its unwavering commitment to innovative health solutions and resilient operational capacity. Known globally as the authority on NAD+ (nicotinamide adenine dinucleotide) and its applications in healthy aging, Niagen Bioscience has demonstrated i...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) 17.70
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 1.37
Price to Sales (Expected) -
Price to Book 2.02
PEG (TTM) -

Financial Strength Current
Quick Ratio -
Working Capital Ratio 5.92
Leverage Ratio (MRQ) 0.31
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) 0.12 $
Revenues (TTM) 1.55 $
Cash Flow (TTM) 0.03 $
Cash -
Book Value 1.05 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 1,045,214
Net Income per Employee (TTM) 87,521
Receivable Turnover Ratio (TTM) 12.8
Inventory Turnover Ratio (TTM) 2.06
Asset Turnover Ratio (TTM) 1.12

Profitability Ratios Current
Gross Margin (MRQ) 62.9 %
Operating Margin (MRQ) -5.84 %
Net Margin (MRQ) -4.31 %
Net Cash Flow Margin (MRQ) 0 %
Effective Tax Rate (TTM) 7.37 %

Management Effectiveness Current
Return On Assets (TTM) 9.4 %
Return On Investment (TTM) 11.34 %
Return On Equity (TTM) 12.62 %
Dividend Yield -
Pay out Ratio (TTM) -



Niagen Bioscience Inc's Segments
Corporate and other Consulting and Other    1.56 % of total Revenue
Tru Niagen Consumer Product    257.04 % of total Revenue
Food Grade Niagen    57.4 % of total Revenue
Pharmaceutical-grade Niagen    6.25 % of total Revenue
NIAGEN Related    320.7 % of total Revenue
Ingredients Pharmaceutical-grade Niagen    4.59 % of total Revenue
Consumer Products    257.04 % of total Revenue
Ingredients    65.29 % of total Revenue





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.